{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Thyroid+Carcinoma&page=2",
    "query": {
      "condition": "Metastatic Thyroid Carcinoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Thyroid+Carcinoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T18:16:00.335Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02062632",
      "title": "Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Carcinoma",
        "Hypopharyngeal Carcinoma",
        "Laryngeal Carcinoma",
        "Lymphoma",
        "Mesothelioma",
        "Metastatic Malignant Neoplasm in the Lung",
        "Metastatic Malignant Neoplasm in the Pleura",
        "Metastatic Malignant Neoplasm in the Spinal Cord",
        "Non-Small Cell Lung Carcinoma",
        "Sarcoma",
        "Small Cell Lung Carcinoma",
        "Thymic Carcinoma",
        "Thymoma",
        "Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Doxepin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2014-04-14",
      "completion_date": "2017-11-06",
      "has_results": true,
      "last_update_posted_date": "2019-10-01",
      "last_synced_at": "2026-07-23T18:16:00.335Z",
      "location_count": 3,
      "location_summary": "Rochester, Minnesota • Omaha, Nebraska • Green Bay, Wisconsin",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Green Bay",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02062632"
    },
    {
      "nct_id": "NCT00068497",
      "title": "Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anaplastic Thyroid Cancer",
        "Insular Thyroid Cancer",
        "Metastatic Parathyroid Cancer",
        "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity",
        "Recurrent Basal Cell Carcinoma of the Lip",
        "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Lymphoepithelioma of the Nasopharynx",
        "Recurrent Lymphoepithelioma of the Oropharynx",
        "Recurrent Metastatic Squamous Neck Cancer With Occult Primary",
        "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity",
        "Recurrent Non-small Cell Lung Cancer",
        "Recurrent Parathyroid Cancer",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Thyroid Cancer",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Stage III Follicular Thyroid Cancer",
        "Stage III Papillary Thyroid Cancer",
        "Stage III Salivary Gland Cancer",
        "Stage III Squamous Cell Carcinoma of the Hypopharynx",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Verrucous Carcinoma of the Larynx",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IV Lymphoepithelioma of the Nasopharynx",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IVA Basal Cell Carcinoma of the Lip",
        "Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVA Follicular Thyroid Cancer",
        "Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVA Lymphoepithelioma of the Oropharynx",
        "Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IVA Papillary Thyroid Cancer",
        "Stage IVA Salivary Gland Cancer",
        "Stage IVA Squamous Cell Carcinoma of the Larynx",
        "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVA Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVA Verrucous Carcinoma of the Larynx",
        "Stage IVA Verrucous Carcinoma of the Oral Cavity",
        "Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IVB Basal Cell Carcinoma of the Lip",
        "Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVB Follicular Thyroid Cancer",
        "Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVB Lymphoepithelioma of the Oropharynx",
        "Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IVB Papillary Thyroid Cancer",
        "Stage IVB Salivary Gland Cancer",
        "Stage IVB Squamous Cell Carcinoma of the Larynx",
        "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVB Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVB Verrucous Carcinoma of the Larynx",
        "Stage IVB Verrucous Carcinoma of the Oral Cavity",
        "Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IVC Basal Cell Carcinoma of the Lip",
        "Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVC Follicular Thyroid Cancer",
        "Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVC Lymphoepithelioma of the Oropharynx",
        "Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IVC Papillary Thyroid Cancer",
        "Stage IVC Salivary Gland Cancer",
        "Stage IVC Squamous Cell Carcinoma of the Larynx",
        "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVC Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IVC Verrucous Carcinoma of the Larynx",
        "Stage IVC Verrucous Carcinoma of the Oral Cavity",
        "Thryoid Gland Nonmedullary Carcinoma",
        "Thyroid Gland Medullary Carcinoma",
        "Tongue Cancer",
        "Untreated Metastatic Squamous Neck Cancer With Occult Primary"
      ],
      "interventions": [
        {
          "name": "gefitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 40,
      "start_date": "2003-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-14",
      "last_synced_at": "2026-07-23T18:16:00.335Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00068497"
    },
    {
      "nct_id": "NCT03099356",
      "title": "Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2017-04-27",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-01",
      "last_synced_at": "2026-07-23T18:16:00.335Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03099356"
    },
    {
      "nct_id": "NCT01286753",
      "title": "A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2011-06",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2016-09-07",
      "last_synced_at": "2026-07-23T18:16:00.335Z",
      "location_count": 9,
      "location_summary": "Torrance, California • New Haven, Connecticut • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01286753"
    },
    {
      "nct_id": "NCT03127098",
      "title": "QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Cancer",
        "Colon Cancer",
        "Ovarian Cancer",
        "Breast Cancer",
        "Lung Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "ETBX-011",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALT-803",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "NantCell, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2017-06-26",
      "completion_date": "2017-12-07",
      "has_results": true,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-07-23T18:16:00.335Z",
      "location_count": 1,
      "location_summary": "Spokane, Washington",
      "locations": [
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03127098"
    },
    {
      "nct_id": "NCT00095836",
      "title": "Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Gefitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2003-03",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2017-05-31",
      "last_synced_at": "2026-07-23T18:16:00.335Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00095836"
    },
    {
      "nct_id": "NCT04579757",
      "title": "Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Solid Tumor",
        "Colorectal Cancer",
        "Neuroendocrine Tumors",
        "Small Cell Lung Cancer",
        "Gastric Cancer",
        "Soft Tissue Sarcoma",
        "Anaplastic Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "Surufatinib and Tislelizumab _ Part 1",
          "type": "DRUG"
        },
        {
          "name": "Surufatinib and Tislelizumab _ Part 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchmed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2021-03-05",
      "completion_date": "2024-08-27",
      "has_results": true,
      "last_update_posted_date": "2025-05-08",
      "last_synced_at": "2026-07-23T18:16:00.335Z",
      "location_count": 18,
      "location_summary": "Tucson, Arizona • Duarte, California • Denver, Colorado + 13 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04579757"
    },
    {
      "nct_id": "NCT01947023",
      "title": "Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Thyroid Gland Carcinoma",
        "Unresectable Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "Dabrafenib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Lapatinib",
          "type": "DRUG"
        },
        {
          "name": "Lapatinib Ditosylate",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2013-09-27",
      "completion_date": "2027-05-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-07-23T18:16:00.335Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01947023"
    },
    {
      "nct_id": "NCT03841617",
      "title": "The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "Thyrogen",
          "type": "DRUG"
        },
        {
          "name": "I-131",
          "type": "RADIATION"
        },
        {
          "name": "I-124",
          "type": "RADIATION"
        },
        {
          "name": "Thyroid hormone withdrawal",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 30,
      "start_date": "2019-07-29",
      "completion_date": "2035-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-07-23T18:16:00.335Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03841617"
    },
    {
      "nct_id": "NCT04552769",
      "title": "Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Cancer",
        "Anaplastic Thyroid Cancer",
        "Undifferentiated Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2020-09-10",
      "completion_date": "2025-01-05",
      "has_results": true,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-07-23T18:16:00.335Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04552769"
    }
  ]
}